-
-
-
-
-
-
-
Exelixis (EXEL) Reiterated at Market Outperform by Citizens Amid Handa Patent Suit
-
-
-
-
-
-
-
Morgan Stanley on Exelixis (EXEL): today's update 'mixed-to-negative at the margin'
-
-
-
-
-
-
-
FDA accepts Exelixis drug application for colorectal cancer treatment
-
-
-
-
-
-
-
BofA Securities Downgrades Exelixis (EXEL) to Underperform
-
-
-
-
-
-
-
Exelixis (EXEL) PT Lowered to $30 at Wells Fargo
-
-
-
-
-
-
-
Goldman Sachs Starts Exelixis (EXEL) at Buy
-
-
-
-
-
-
-
Exelixis (EXEL) Tops Q2 EPS by 11c, provides guidance
-
479,072 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


